USA – Vizgen, a Cambridge, MA-based life science company, closed an $85.2 million Series C financing.
The round was led by Blue Water Life Science Advisors with participation from ARCH Venture Partners, Sofina, Northpond Ventures, Tao Capital Partners, Novalis LifeSciences, and David Walt.The company intends to use the funds to accelerate growth, expand operations and its business reach.Led by CEO Terry Lo, Vizgen is dedicated to providing tools that are enabling researchers to gain new insight into the biological systems that govern human health and disease with spatial context. The company’s MERSCOPE Platform – based on the MERFISH technology developed in the laboratory of Dr. Xiaowei Zhuang, a Howard Hughes Medical Institute Investigator, and the David B. Arnold, Jr. Professor of Science at Harvard University – enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. MERSCOPE provides insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, cell and gene therapy, and is an essential tool for accelerating drug discovery and development. Vizgen announced broad U.S. availability of its platform in January 2022.03/06/2022
